The Estée Lauder group announced on Thursday, April 30, a minority investment in 111SKIN, a luxury clinical skin care brand founded in 2012 by plastic and reconstructive surgeon Dr. Yannis Alexandrides and his wife Eva. Terms of the investment were not disclosed.
Originally developed to accelerate post-procedure healing, 111SKIN harnesses a proprietary complex — NAC Y2 — designed to support skin repair while promoting a healthy, radiant, and resilient complexion.
The brand has developed a portfolio of more than 30 products, priced from USD 50 to USD 1,000. 111SKIN operates in a fast-growing segment where medical expertise and powerful high-performance formulations meet.
“Skin care is entering a new phase, shaped by the convergence of procedures, longevity and beauty, as consumers increasingly seek products that deliver visible, treatment-inspired results,” said Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies. “111SKIN exemplifies this shift, translating Dr. Alexandrides’ more than 35 years of surgical and aesthetic treatment experience into high-performance luxury skin care inspired by in-clinic treatments and built on clinical insight, next-generation actives, powerful formulas and proven efficacy.”
111SKIN distributes through luxury retail, e-commerce and high-end spa channels – including Harrods, Bluemercury, Nordstrom, Mandarin Oriental, and Aman – and has a robust direct-to-consumer business representing approximately 20% of sales, reflecting strong digital engagement with prestige consumers.
The brand has a diversified global footprint, with North America representing approximately 40% of 2025 sales, and an established presence across China, the United Kingdom, Europe and Asia Pacific.
Dr. Alexandrides will remain actively involved in the brand and will continue to lead 111SKIN alongside its experienced management team, including CEO Vanessa Goddevrind.
